Pharma stock skyrockets 16% after announcing strong Q4 results and dividend

Synopsis:- Shares surged 16% after strong Q4CY25 results, with revenue rising 47% YoY to  Rs 251 crore and net profit climbing 50% to  Rs 66 crore. Operating profit improved to  Rs 90 crore over the year, while a  Rs 75 per share dividend further boosted investor sentiment.

The shares of the pharmaceutical company jumped up to 16 percent in today’s trading session from the day’s high after the company reported skyrocketing Q4CY25 earnings.

With a market capitalization of Rs 10,628.63 crore, the shares of Sanofi Consumer Healthcare India Ltd were trading at Rs 4,615.00 per share, increasing around 15.21 percent as compared to the previous closing price of Rs 4,005.75 apiece.

Q4CY25 Highlights

The shares of Sanofi Consumer Healthcare India Limited have seen bullish movement after announcing its robust financial performance in Q4CY25, in which revenue increased by 47 percent on a year-on-year basis from Rs 171 crore in Q4CY24 to Rs 251 crore in Q4CY25. However, on a Quarter-on-Quarter basis, revenue increased by 7 percent from Rs 234 crore in Q2CY26 to Rs 251 crore in Q4CY25.

Moreover, net profit increased by 50 percent on a yearly basis from Rs 44 crore in Q4CY24 to Rs 66 crore in Q4CY25, meanwhile, on a quarter-on-quarter basis, net profit increased by 5 percent from Rs 63 crore in Q2CY26 to Rs 66 crore in Q4CY25.

The company has recommended a final dividend of  Rs 75 per equity share with a face value of  Rs 10 for 2025, subject to shareholder approval at the upcoming AGM. The payout reflects strong financial health and confidence in cash flows, rewarding shareholders while maintaining a balanced capital allocation strategy.

Between December 2024 and December 2025, operating performance remained stable with gradual improvement. Operating profit increased from  Rs 62 crore in Dec 2024 to  Rs 90 crore in Dec 2025, reflecting better cost absorption and sales recovery. However, OPM stayed largely steady at 36% during the period, indicating consistent margin management despite fluctuating quarterly trends.

Commenting on the full year results, Amit Jain, Chairman, Sanofi Consumer Healthcare India Limited said, “Our full-year performance reflects the strength of our strategy and the disciplined execution by our teams. By driving sustained growth, deepening penetration of our portfolio, and

accelerating digital transformation, we delivered meaningful outcomes for all our stakeholders. Our strong financial performance this year enables us to reward shareholders with a healthy dividendof Rs 75 per share.”

Sanofi Consumer Healthcare India Limited is a leading player in India’s over-the-counter healthcare market, offering trusted brands across vitamins, pain relief, and digestive wellness segments. Backed by strong global parentage, the company focuses on science-driven products, brand strength, and wide distribution to deliver consistent growth and consumer trust.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Pharma stock skyrockets 16% after announcing strong Q4 results and dividend appeared first on Trade Brains.